CLINICAL TRIAL: REVEAL II

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 基因和其他生物标志物正在迅速得到鉴定，它们可以提供症状前估计或个人最终发展为复杂迟发性疾病的风险。 最近发现的许多遗传标记不是决定性基因，而是与其他尚未确定的基因相互作用的易感基因，以及年龄，性别，种族，家族史和环境暴露等因素。 公众对获得风险信息有着广泛的兴趣，并且广泛的共识是，很快就会开发出治疗方法来减缓或预防退行性疾病的发生。 由于对遗传易感性测试的营销和利用几乎没有限制，其使用可能很快会增加。 然而，很少或没有数据可以用来了解谁，例如，年龄、性别、种族将寻求遗传易感性风险信息，一旦它是可用的;以及为什么他们会这样做，例如，以获得治疗，以减轻焦虑，以准备财政。 更重要的是，几乎没有关于提供敏感性风险信息的潜在益处或负面后果的信息，这些信息可以指导合理的临床决策或公共政策。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Genes and other biological markers are rapidly being identified that can provide presymptomatic estimates or risk to individuals for the eventual development of complex late-onset diseases. Many of the recently discovered genetic markers are not deterministic genes, but rather susceptibility genes that interact with other, as yet unidentified genes, and with factors such as age, gender, race, family history and environmental exposures. There is widespread public interest in obtaining risk information, and a broad consensus that treatments will soon be developed to slow or prevent the onset of degenerative disease. With few restrictions on the marketing and utilization of genetic susceptibility tests, their use may soon increase. Nevertheless, there are little or no data available to understand who( e.g., age, gender, race) will seek genetic susceptibility risk information once it is available; and why they would do so (e.g. to obtain treatment , to alleviate anxiety, to prepare financially). Even more importantly, there is little information on the potential benefits or negative consequences of providing susceptibility risk information that could guide rational clinical decisions or public policy.